MedTrace Logo

5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results

NCT02355574 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 301

Last updated 2021-10-08

No results posted yet for this study

Summary

The INTEGRATE Registry Study follows patients with cutaneous melanoma who have had the DecisionDx-Melanoma gene expression assay performed. Data will be collected through review of medical records from clinical visits with physician.

The purpose is to document the clinical application of results obtained from the DecisionDx- Melanoma multi-gene assay and to track outcomes of patients for whom DecisionDx-Melanoma testing has been completed. Additionally the study will assess the health economic impact of DecisionDx-Melanoma testing as it relates to the Melanoma population.

Conditions

Sponsors & Collaborators

  • Castle Biosciences Incorporated

    lead INDUSTRY

Principal Investigators

  • Robert Cook, PhD · Castle Biosciences Inc.

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2021-02-28
Completion
2021-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02355574 on ClinicalTrials.gov